Anna Kruschinski
Berlin, BE 10589, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.
Journal: Oncotarget
Published: July 08, 2017
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Journal: Leukemia
Published: January 12, 2017
CXCL12/SDF-1-Dependent Retinal Migration of Endogenous Bone Marrow-Derived Stem Cells Improves Visual Function after Pharmacologically Induced Retinal Degeneration.
Journal: Stem cell reviews and reports
Published: December 08, 2016
Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNγ.
Journal: Cancer research
Published: October 10, 2014
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Journal: Cell reports
Published: January 23, 2014
The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.
Journal: Blood
Published: November 27, 2013
Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12.
Journal: Clinical pharmacology and therapeutics
Published: April 17, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026